Cargando…
Efficacy and safety of pharmacological interventions in second- or later-line treatment of patients with advanced soft tissue sarcoma: a systematic review
BACKGROUND: Current guidelines recommend anthracycline-based chemotherapy primarily with doxorubicin either as monotherapy or in combination with ifosfamide as the first-line treatment for most advanced STS subtypes. Therapeutic options after failure of doxorubicin and/or ifosfamide are limited. Thi...
Autores principales: | Sharma, Sheetal, Takyar, Shweta, Manson, Stephanie C, Powell, Sarah, Penel, Nicolas |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3765173/ https://www.ncbi.nlm.nih.gov/pubmed/23937858 http://dx.doi.org/10.1186/1471-2407-13-385 |
Ejemplares similares
-
Clinical Benefit of Second-Line Palliative Chemotherapy in Advanced Soft-Tissue Sarcoma
por: Minchom, Anna, et al.
Publicado: (2010) -
Frequency of Certain Established Risk Factors in Soft Tissue Sarcomas in Adults: A Prospective Descriptive Study of 658 Cases
por: Penel, Nicolas, et al.
Publicado: (2008) -
High Prevalence of 5T4/Trophoblast Glycoprotein in Soft Tissue Sarcomas
por: Groothuis, Patrick, et al.
Publicado: (2021) -
Study protocol of REGOSARC trial: activity and safety of regorafenib in advanced soft tissue sarcoma: a multinational, randomized, placebo-controlled, phase II trial
por: Brodowicz, Thomas, et al.
Publicado: (2015) -
Cost-Effectiveness of Pazopanib in Advanced Soft Tissue Sarcoma in the United Kingdom
por: Amdahl, Jordan, et al.
Publicado: (2014)